Literature DB >> 23568263

Transient photoreceptor deconstruction by CNTF enhances rAAV-mediated cone functional rescue in late stage CNGB3-achromatopsia.

András M Komáromy1, Jessica S Rowlan, Amanda T Parton Corr, Shelby L Reinstein, Sanford L Boye, Ann E Cooper, Amaliris Gonzalez, Britt Levy, Rong Wen, William W Hauswirth, William A Beltran, Gustavo D Aguirre.   

Abstract

Achromatopsia is a genetic disorder of cones, and one of the most common forms is a channelopathy caused by mutations in the β-subunit, CNGB3, of the cone cyclic nucleotide-gated (CNG) channel. Recombinant adeno-associated virus of serotype 5 (rAAV5)-mediated gene transfer of human CNGB3 cDNA to mutant dog cones results in functional and structural rescue in dogs <0.5 years of age, but treatment is minimally effective in dogs >1 year. We now test a new therapeutic concept by combining gene therapy with the administration of ciliary neurotrophic factor (CNTF). Intravitreal CNTF causes transient dedifferentiation of photoreceptors, a process called deconstruction, whereby visual cells become immature with short outer segments, and decreased retinal function and gene expression that subsequently return to normal. Cone function was successfully rescued in all mutant dogs treated between 14 and 42 months of age with this strategy. CNTF-mediated deconstruction and regeneration of the photoreceptor outer segments prepares the mutant cones optimally for gene augmentation therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23568263      PMCID: PMC3677296          DOI: 10.1038/mt.2013.50

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  50 in total

1.  Gene therapy restores vision in a canine model of childhood blindness.

Authors:  G M Acland; G D Aguirre; J Ray; Q Zhang; T S Aleman; A V Cideciyan; S E Pearce-Kelling; V Anand; Y Zeng; A M Maguire; S G Jacobson; W W Hauswirth; J Bennett
Journal:  Nat Genet       Date:  2001-05       Impact factor: 38.330

2.  Rod disc turnover in the dog.

Authors:  N Buyukmihci; G D Aguirre
Journal:  Invest Ophthalmol       Date:  1976-07

3.  Gene replacement therapy in the retinal degeneration slow (rds) mouse: the effect on retinal degeneration following partial transduction of the retina.

Authors:  G M Sarra; C Stephens; M de Alwis; J W Bainbridge; A J Smith; A J Thrasher; R R Ali
Journal:  Hum Mol Genet       Date:  2001-10-01       Impact factor: 6.150

4.  Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy.

Authors:  R R Ali; G M Sarra; C Stephens; M D Alwis; J W Bainbridge; P M Munro; S Fauser; M B Reichel; C Kinnon; D M Hunt; S S Bhattacharya; A J Thrasher
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

5.  Genetic basis of total colourblindness among the Pingelapese islanders.

Authors:  O H Sundin; J M Yang; Y Li; D Zhu; J N Hurd; T N Mitchell; E D Silva; I H Maumenee
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

6.  Endoplasmic reticulum stress-associated cone photoreceptor degeneration in cyclic nucleotide-gated channel deficiency.

Authors:  Arjun Thapa; Lynsie Morris; Jianhua Xu; Hongwei Ma; Stylianos Michalakis; Martin Biel; Xi-Qin Ding
Journal:  J Biol Chem       Date:  2012-04-09       Impact factor: 5.157

7.  Canine CNGB3 mutations establish cone degeneration as orthologous to the human achromatopsia locus ACHM3.

Authors:  Duska J Sidjanin; Jennifer K Lowe; John L McElwee; Bruce S Milne; Taryn M Phippen; David R Sargan; Gustavo D Aguirre; Gregory M Acland; Elaine A Ostrander
Journal:  Hum Mol Genet       Date:  2002-08-01       Impact factor: 6.150

Review 8.  Cyclic nucleotide-gated ion channels.

Authors:  Kimberly Matulef; William N Zagotta
Journal:  Annu Rev Cell Dev Biol       Date:  2003       Impact factor: 13.827

9.  Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa.

Authors:  Weng Tao; Rong Wen; Moses B Goddard; Sandy D Sherman; Pam J O'Rourke; Paul F Stabila; William J Bell; Brenda J Dean; Konrad A Kauper; Veronica A Budz; William G Tsiaras; Gregory M Acland; Sue Pearce-Kelling; Alan M Laties; Gustavo D Aguirre
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-10       Impact factor: 4.799

10.  AAV2 gene therapy readministration in three adults with congenital blindness.

Authors:  Jean Bennett; Manzar Ashtari; Jennifer Wellman; Kathleen A Marshall; Laura L Cyckowski; Daniel C Chung; Sarah McCague; Eric A Pierce; Yifeng Chen; Jeannette L Bennicelli; Xiaosong Zhu; Gui-Shuang Ying; Junwei Sun; J Fraser Wright; Alberto Auricchio; Francesca Simonelli; Kenneth S Shindler; Federico Mingozzi; Katherine A High; Albert M Maguire
Journal:  Sci Transl Med       Date:  2012-02-08       Impact factor: 17.956

View more
  38 in total

Review 1.  Gene replacement therapy for retinal CNG channelopathies.

Authors:  Christian Schön; Martin Biel; Stylianos Michalakis
Journal:  Mol Genet Genomics       Date:  2013-07-17       Impact factor: 3.291

2.  Chapter 3 - Restoring Vision to the Blind: Gene Therapy for Vision Loss.

Authors: 
Journal:  Transl Vis Sci Technol       Date:  2014-12-30       Impact factor: 3.283

Review 3.  Let There Be Light: Gene and Cell Therapy for Blindness.

Authors:  Deniz Dalkara; Olivier Goureau; Katia Marazova; José-Alain Sahel
Journal:  Hum Gene Ther       Date:  2016-02       Impact factor: 5.695

4.  Successful arrest of photoreceptor and vision loss expands the therapeutic window of retinal gene therapy to later stages of disease.

Authors:  William A Beltran; Artur V Cideciyan; Simone Iwabe; Malgorzata Swider; Mychajlo S Kosyk; Kendra McDaid; Inna Martynyuk; Gui-Shuang Ying; James Shaffer; Wen-Tao Deng; Sanford L Boye; Alfred S Lewin; William W Hauswirth; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

5.  Limited time window for retinal gene therapy in a preclinical model of ciliopathy.

Authors:  Poppy Datta; Avri Ruffcorn; Seongjin Seo
Journal:  Hum Mol Genet       Date:  2020-08-11       Impact factor: 6.150

6.  Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector.

Authors:  Artur V Cideciyan; Raghavi Sudharsan; Valérie L Dufour; Michael T Massengill; Simone Iwabe; Malgorzata Swider; Brianna Lisi; Alexander Sumaroka; Luis Felipe Marinho; Tatyana Appelbaum; Brian Rossmiller; William W Hauswirth; Samuel G Jacobson; Alfred S Lewin; Gustavo D Aguirre; William A Beltran
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-20       Impact factor: 11.205

7.  Loss of retinitis pigmentosa 2 (RP2) protein affects cone photoreceptor sensory cilium elongation in mice.

Authors:  Linjing Li; Kollu Nageswara Rao; Yun Zheng-Le; Toby W Hurd; Concepción Lillo; Hemant Khanna
Journal:  Cytoskeleton (Hoboken)       Date:  2015-10-14

Review 8.  Promising and delivering gene therapies for vision loss.

Authors:  Livia S Carvalho; Luk H Vandenberghe
Journal:  Vision Res       Date:  2014-08-02       Impact factor: 1.886

9.  Mid-stage intervention achieves similar efficacy as conventional early-stage treatment using gene therapy in a pre-clinical model of retinitis pigmentosa.

Authors:  Katherine J Wert; Javier Sancho-Pelluz; Stephen H Tsang
Journal:  Hum Mol Genet       Date:  2013-09-18       Impact factor: 6.150

Review 10.  Neuroprotective strategies for retinal disease.

Authors:  Machelle T Pardue; Rachael S Allen
Journal:  Prog Retin Eye Res       Date:  2018-02-23       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.